Skip to main content

Lee Woo-in

Kyung Hee University · Medicine

About the Lab

Professor Lee Woo-in's research lab specializes in the molecular characterization and functional analysis of drug transporters, particularly organic anion transporting polypeptides (OATPs), with a focus on their roles in drug disposition, tissue penetration, and cancer biology. The lab investigates genetic polymorphisms in transporter genes such as SLCO1A2 and SLCO1B3, exploring their impact on interindividual variability in drug response and toxicity. A key research direction involves the aberrant expression of OATP1B3 in colorectal and pancreatic cancers, linking transporter overexpression to tumor progression and chemotherapeutic response. The lab also examines the structural and mechanical properties of biomaterials like PEEK and its composites, particularly in relation to crystallinity and performance in biomedical applications.

drug transportersOATP1B3pharmacogenomicscancer drug responsebiomaterials

Research Overview

Papers
411
Total Citations
7,690
Papers (5y)
94
Primary Field
Medicine

Research Output Trend

Figures are computed from collected data and may differ slightly.

Publications per year (5y)
94total
2022
2023
2024
2025
2026
Citations per year (5y)
103total
20222023202420252026

Selected Papers

15
1
Article|359 citations·2005
Polymorphisms in Human Organic Anion-transporting Polypeptide 1A2 (OATP1A2)
Wooin Lee, Hartmut Glaeser, Layton H. Smith, Richard Roberts, Gilbert Moeckel, Guillermo Gervasini, Brenda F. Leake, Richard B. Kim
SJR Q1Journal of Biological ChemistryOA

Organic anion-transporting polypeptide 1A2 (OATP1A2) is a drug uptake transporter known for broad substrate specificity, including many drugs in clinical use. Therefore, genetic variation in SLCO1A2 may have important implications to the disposition and tissue penetration of substrate drugs. In the present study, we demonstrate OATP1A2 protein expression in human brain capillary and renal distal nephron using immunohistochemistry. We also determined the extent of single nucleotide polymorphisms

OncologyMedicine
2
Review|222 citations·2004
Transporters and Renal Drug Elimination
Wooin Lee, Richard B. Kim
SJR Q1The Annual Review of Pharmacology and Toxicology

Carrier-mediated processes, often referred to as transporters, play key roles in the reabsorption and secretion of many endogenous and xenobiotic compounds by the kidney. The renal proximal tubule is the primary site of active transport for a wide variety of substrates, including organic anions/cations, peptides, and nucleosides. During the past decade, significant advances in molecular identification and characterization of transporter proteins have been made. Although it is generally noted tha

OncologyMedicine
3
Review|139 citations·2018
Next-generation proteasome inhibitors for cancer therapy
Ji Eun Park, Zachary Miller, Yearin Jun, Wooin Lee, Kyung Bo Kim
SJR Q1Translational research
HematologyMedicine
4
Article|130 citations·2008
Overexpression of OATP1B3 Confers Apoptotic Resistance in Colon Cancer
Wooin Lee, Abbes Belkhiri, A. Craig Lockhart, Nipun B. Merchant, Hartmut Glaeser, Elizabeth I. Harris, M. Kay Washington, Elizabeth M. Brunt, Alex Zaika, Richard B. Kim, Wael El‐Rifai
SJR Q1Cancer ResearchOA

Organic anion transporting polypeptide 1B3 (OATP1B3, SLCO1B3) is normally expressed in hepatocytes. In this study, we showed frequent overexpression of OATP1B3 in colorectal adenocarcinomas. Quantitative reverse transcription-PCR analysis of 17 colon tumors indicated tumoral overexpression of OATP1B3 by approximately 100-fold, compared with 20 normal colon samples (P < 0.0001). Using immunohistochemistry on a tissue microarray containing 93 evaluable colon tumor specimens, we detected immunostai

OncologyMedicine
5
Review|125 citations·2005
Cancer Pharmacogenomics: Powerful Tools in Cancer Chemotherapy and Drug Development
Wooin Lee, A. Craig Lockhart, Richard B. Kim, Mace L. Rothenberg
SJR Q1The Oncologist

Abstract Learning Objectives After completing this course, the reader will be able to: Explain how genetic factors contribute to variability in drug response. Apply this understanding to clinical outcomes in patients treated with specific chemotherapy agents. Describe approaches for improving clinical cancer therapy and cancer drug development. Access and take the CME test online and receive 1 hour of AMA PRA category 1 credit at CME.TheOncologist.com Interindividual differences in tumor respons

Molecular BiologyBiochemistry, Genetics and Molecular Biology
6
Article|93 citations·1987
Effects of Cooling Rate on the Crystallinity and Mechanical Properties of Thermoplastic Composites
Woo In Lee, Margaret F. Talbott, George Ś. Springer, Lars A. Berglund
SJR Q2Journal of Reinforced Plastics and Composites

Tests were performed to evaluate the effects of crystallinity on the mechanical properties of PEEK 150P polymer and APC-2 graphite/PEEK composite. The tensile strengths, ten sile moduli and fracture toughnesses of the polymer, and the mixed mode I and mode II fracture toughnesses of the composite were measured at crystallinities ranging from 27 to 43 percent by weight. The results show that, in the crystallinity range studied, the tensile properties are not affected significantly by changes in c

Polymers and PlasticsMaterials Science
7
Article|84 citations·2012
A Cancer-Specific Variant of the SLCO1B3 Gene Encodes a Novel Human Organic Anion Transporting Polypeptide 1B3 (OATP1B3) Localized Mainly in the Cytoplasm of Colon and Pancreatic Cancer Cells
Nilay Thakkar, Kyungbo Kim, Eun Ryoung Jang, Song‐Hee Han, Kyung-Hwa Kim, Donghern Kim, Nipun B. Merchant, A. Craig Lockhart, Wooin Lee
SJR Q1Molecular Pharmaceutics

OATP1B3 is a member of the OATP (organic anion transporting polypeptides) superfamily, responsible for mediating the transport of numerous endogenous and xenobiotic substances. Although initially reported to be exclusively expressed in the liver, several studies reported that OATP1B3 is frequently expressed in multiple types of cancers and may be associated with differing clinical outcomes. However, a detailed investigation on the expression and function of OATP1B3 protein in cancer has been lac

OncologyMedicine
8
Article|58 citations·2019
Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation
Ji Eun Park, Joonyoung Park, Yearin Jun, Yunseok Oh, Gongmi Ryoo, Yoo-Seong Jeong, Hytham H. Gadalla, Jee Sun Min, Jung Hwan Jo, Myung Geun Song, Keon Wook Kang, Soo Kyung Bae
SJR Q1Journal of Controlled Release
HematologyMedicine
9
Article|55 citations·2012
Development of Peptide-Based Reversing Agents for P-Glycoprotein-Mediated Resistance to Carfilzomib
Lin Ao, Ying Wu, Donghern Kim, Eun Ryoung Jang, Kyung-Hwa Kim, Do-Min Lee, Kyung Bo Kim, Wooin Lee
SJR Q1Molecular Pharmaceutics

Carfilzomib is a novel class of peptidyl epoxyketone proteasome inhibitor and has demonstrated promising activity in multiple clinical trials to treat patients with multiple myeloma and other types of cancers. Here, we investigated molecular mechanisms underlying acquired resistance to carfilzomib and a potential strategy to restore cellular sensitivity to carfilzomib. H23 and DLD-1 cells (human lung and colon adenocarcinoma cell lines) with acquired resistance to carfilzomib displayed marked cr

HematologyMedicine
10
Article|49 citations·2010
The prevalence of “anti‐HBc alone” and HBV DNA detection among anti‐HBc alone in Korea
So‐Young Kang, Myeong-Hee Kim, Woo‐In Lee
SJR Q1Journal of Medical Virology

The "anti-HBc alone" is a frequent serological finding in clinical laboratories, making it difficult to determine whether the HBV infection has resolved. The objectives of this study were to investigate the prevalence of anti-HBc alone and HBV DNA detection (occult HBV infection) among anti-HBc alone, and to describe the demographic and clinical characteristics of anti-HBc alone. A total of 17,677 sera referred from the Health Promotion Center (HPC group, 4,014 sera) as well as all the hospital

EpidemiologyMedicine
11
Review|46 citations·2020
Post-translational regulation of the major drug transporters in the families of organic anion transporters and organic anion–transporting polypeptides
Wooin Lee, Jeong-Min Ha, Yuichi Sugiyama
SJR Q1Journal of Biological ChemistryOA

genetic, environmental, and disease-related factors, drug-drug interactions, and food-drug interactions) can lead to variations in the expression and activity of the anion drug-transporting proteins of OATs and OATPs, possibly impacting the therapeutic outcomes. Previous investigations mainly focused on the regulation at the transcriptional level and drug-drug interactions as competing substrates or inhibitors. Recently, evidence has accumulated that cellular trafficking, post-translational modi

OncologyMedicine
12
Article|41 citations·2019
Neutrophil-to-Monocyte-Plus-Lymphocyte Ratio as a Potential Marker for Discriminating Pulmonary Tuberculosis from Nontuberculosis Infectious Lung Diseases
You La Jeon, Wooin Lee, So Young Kang, Myeong Hee Kim
SJR Q3Laboratory Medicine

OBJECTIVE: To determine whether NMLR has more statistical strength than NLR in discriminating TB from non-TB infectious lung diseases. METHODS: Among patients who underwent 3 or more TB culture tests with molecular study between January 2016 and December 2017, 110 patients with TB, and 159 patients diagnosed with non-TB infectious lung diseases were enrolled. The original complete blood count (CBC) parameters and modified CBC indices, including NLR and NMLR, were analyzed. RESULTS: The NLR and N

Infectious DiseasesMedicine
13
Article|38 citations·2017
Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice
Ji Eun Park, Se‐Eun Chun, Derek Reichel, Jee Sun Min, Su-Chan Lee, Song‐Hee Han, Gongmi Ryoo, Yunseok Oh, Shin‐Hyung Park, Heon-Min Ryu, Kyung Bo Kim, Ho‐Young Lee
SJR Q1PLoS ONEOA

Carfilzomib (CFZ) is a peptide epoxyketone proteasome inhibitor approved for the treatment of multiple myeloma (MM). Despite the remarkable efficacy of CFZ against MM, the clinical trials in patients with solid cancers yielded rather disappointing results with minimal clinical benefits. Rapid degradation of CFZ in vivo and its poor penetration to tumor sites are considered to be major factors limiting its efficacy against solid cancers. We previously reported that polymer micelles (PMs) composed

HematologyMedicine
14
Article|34 citations·2005
Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma
Soyoung Kang, Jin‐Tae Suh, Hee-Joo Lee, Hwi‐Joong Yoon, Wooin Lee
SJR Q2Annals of Hematology
HematologyMedicine
15
Article|34 citations·2013
Role of hypoxia inducible factor-1α in the regulation of the cancer-specific variant of organic anion transporting polypeptide 1B3 (OATP1B3), in colon and pancreatic cancer
Song‐Hee Han, Kyungbo Kim, Nilay Thakkar, Donghak Kim, Wooin Lee
SJR Q1Biochemical Pharmacology
Cancer ResearchBiochemistry, Genetics and Molecular Biology

Research Areas

OncologyMolecular BiologyHematologyPulmonary and Respiratory MedicineEpidemiologyPharmacology

Dive deeper into Lee Woo-in's research on Nubint

Open this lab's papers in the app to read with AI, summarize, and cite in your writing.